MNG1103
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.444
- KRAS_SIGNALING_DN+0.340
- ESTROGEN_RESPONSE_LATE+0.286
- COAGULATION+0.281
- PANCREAS_BETA_CELLS+0.207
- P53_PATHWAY+0.184
- XENOBIOTIC_METABOLISM+0.175
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.173
- TNFA_SIGNALING_VIA_NFKB+0.173
- HYPOXIA+0.162
Top 10 suppressed
- G2M_CHECKPOINT-0.500
- E2F_TARGETS-0.472
- MITOTIC_SPINDLE-0.440
- PROTEIN_SECRETION-0.430
- UV_RESPONSE_DN-0.371
- MYC_TARGETS_V1-0.341
- PI3K_AKT_MTOR_SIGNALING-0.330
- MTORC1_SIGNALING-0.310
- UNFOLDED_PROTEIN_RESPONSE-0.305
- ANDROGEN_RESPONSE-0.256
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-LD-A66U-01A-11R-A31O-07 | — | B | 0.899 |
| 2 | TCGA-E9-A3X8-01A-31R-A22U-07 | — | B | 0.893 |
| 3 | TCGA-A2-A3XW-01A-11R-A239-07 | — | B | 0.883 |
| 4 | TCGA-OL-A66L-01A-12R-A31O-07 | — | B | 0.877 |
| 5 | SJEPD012_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.874 |
| 6 | TCGA-B6-A401-01A-11R-A239-07 | — | B | 0.870 |
| 7 | SJEPD035_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.846 |
| 8 | MDT-AP-0720 | Med | Medulloblastoma | 0.841 |
| 9 | SJEPD028_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.839 |
| 10 | SRR1443895 | GTEX | — | 0.838 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.444 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.340 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.286 | Idelalisib | — uncovered |
| COAGULATION | 0.281 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.207 | Cobimetinib | — uncovered |
| P53_PATHWAY | 0.184 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.175 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.173 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.173 | Inavolisib | — uncovered |
| HYPOXIA | 0.162 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.139 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.134 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.098 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.090 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.074 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.072 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.071 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.070 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.068 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.049 | Remibrutinib | — uncovered |